Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy

Francesco Pichi, Paola Carrai, Antonio Ciardella, Francine Behar-Cohen, Paolo Nucci, Central Serous Chorioretinopathy Study Group The Central Serous Chorioretinopathy Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the effect of oral spironolactone and eplerenone, two specific antagonists of the mineralocorticoid receptor, in central serous chorioretinopathy (CSCR). Methods: In this prospective, placebo-controlled trial, sixty patients with persistent CSCR were assigned to three treatment group. Twenty patients in Group 1 were treated with 25 mg of spironolactone (Aldactone; Pfizer) for 1 week, then increased to 50 mg for the following 3 weeks, then shifted to eplerenone 50 mg for 1 month. Twenty patients in Group 2 were treated with 25 mg of eplerenone (Inspra; Pfizer) for 1 week, then increased to 50 mg for the following 3 weeks, and then shifted to spironolactone 50 mg for 1 month. Twenty patients in Group 3 were treated with 1 placebo control tablet for 1 week, then increased to two tablets for the following 3 weeks, and then shifted to spironolactone 50 mg for 1 month. At the end of the second month, all the treatments were stopped, and the patients were followed for two additional months. Primary outcome measure was a change in BCVA at 1, 2, and 4 months. Secondary outcome was a change of >20 % in the size of SRF recorded with OCT at 1, 2, and 4 months of treatment. Results: In terms of BCVA, treatment in Group 1 was effective from the first month (spironolactone, p value 0.01), and in Group 2 effective from the second month (shift to spironolactone, p value 0.004). Since the p value after the first month was 0.2 in Group 2, even with a larger sample, it would be difficult to see an efficacy of an eplerenone treatment after 1 month. As for the SRF, both in Group 1 and Group 2, both treatments were found to be equally effective after 1 month of administration (p values 0.004). At 4 months, only in Group 3, there was no statistical improvement of BCVA and SRF (p values 0.09 and 0.5). Conclusions: Spironolactone is statistically superior to eplerenone in improving BCVA of patients with CSCR, while both drugs can be considered equally effective in promoting the reabsorption of SRF.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalInternational Ophthalmology
DOIs
Publication statusAccepted/In press - Oct 18 2016

Keywords

  • Central serous chorioretinopathy
  • Eplerenone
  • Mineralocorticoid
  • Spironolactone

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy'. Together they form a unique fingerprint.

Cite this